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Abstract Clinical and radiological
changes in tuberculous meningitis
(TBM) have been reported but there
is paucity of comprehensive serial
clinicoradiological follow-up. In this
prospective hospital based study, we
investigated serial changes in the
clinical and radiological findings and
their relationships over 6 months in
31 consecutive patients with TBM,
diagnosed on the basis of clinical,
radiological and spinal fluid criteria.
We graded the severity of the TBM
as I–III. Detailed clinical examina-
tion, contrast-enhanced CT and
activities of daily living (ADL)
assessments were made on admis-
sion, and 3 and 6 months after
therapy. Further CT was carried out
as required. Patients received four-
drug antituberculous therapy
(RHZE) and underwent a ventricu-
loperitoneal shunt if necessary.
Outcome was defined as poor, par-
tial or complete recovery using the
Barthel index score at 6 months. The
age of the patients was 6–80 years,
mean 35.2 years; four were children
and 13 female. Meningitis was
stage I in 5, stage II in six and
stage III in 20 patients. Focal
weakness was present in nine,
papilloedema in six and ophthal-
moplegia in ten. There were ten
patients who deteriorated within
first 6 weeks of therapy. Mean
Glasgow coma score (GCS) deteri-
orated from 12.5 to 11.4; the grade
of meningitis increased by two stages
in one patient, one stage in another,
and motor deficits appeared in four
and optic atrophy in four; four pa-
tients required shunt surgery. By
3 months most patients were stable.
At 6 months 17 patients had com-
plete, four partial and nine poor re-
covery. Initial CT was abnormal in
28 patients, revealing hydrocephalus
and exudates in 15 each, infarcts in
ten and tuberculomas in 13. It was
repeated in ten patients who deteri-
orated, showing new abnormalities
such as hydrocephalus in two, in-
farcts in four, exudates in four and
granulomas in two, with worsening
of the previous findings. CT at 3 and
6 months was still abnormal in most
patients. At 6 months hydrocepha-
lus had disappeared in four, as had
tuberculomas in seven and exudates
in six, but infarcts did not change.
Initial deterioration was related to
weakness on admission and the
GCS. Cognitive impairment signifi-
cantly correlated with exudates and
tuberculomas and motor deficits
with infarcts. Thus, a third of pa-
tients with TBM may deteriorate
within 6 weeks of starting treatment
and CT can be helpful in managing
them. Worsening on treatment was
related to weakness and GCS on
admission. In most patients CT
remained abnormal at 6 months
despite clinical recovery.
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Introduction
Tuberculous meningitis (TBM) is the commonest sub-
acute meningitis in developing countries. Even in the
developed countries its incidence has been rising because
of AIDS, organ transplantation and the use of immu-
nosuppressive drugs. With antituberculous therapy,
improvement may begin after weeks to months; the
patients may worsen, and subsequently recover [1, 2]. It
is therefore of interest to monitor the clinical findings
closely and to repeat CT studies if appropriate. The
literature contained only two studies in which serial
changes have been reported. In one, the importance of
basal exudates resulting in infarcts and hydrocephalus
was highlighted. Development of radiological abnor-
malities during treatment and their persistence even after
a year have been reported [3]. In other study enhancing
exudates were associated with poorer outcome than
nonenhancing exudates [4]. These studies, however, were
retrospective, follow-up was not uniform and did not
address clinicoradiological correlations, especially
changes during the treatment and the factors responsible
for worsening of the clinical picture. We report serial
clinical and radiological changes in TBM and analyse
the clinical and radiological findings which may be as-
sociated with worsening during treatment.
Materials and methods
We studied 31 consecutive patients with TBM seen during 1999–
2001. The diagnosis was based on clinical, radiological and spinal
fluid (CSF) criteria. Essential criteria included fever, headache and
neck stiffness for more than 2 weeks in patients in whom malaria,
septic and fungal meningitis were excluded. Supportive criteria
included predominant lymphocytic pleocytosis and raised protein
in the CSF; CT findings such as exudates, hydrocephalus, tuber-
culomas or infarcts singly or in combination; evidence of tuber-
culosis outside the central nervous system (CNS); and a response to
antituberculous therapy. The essential criteria plus three of the four
supportive criteria were considered suggestive [5]. The presence of
acid-fast bacilli (AFB) in the CSF, and a positive polymerase chain
reaction, IgM ELISA or culture for AFB were considered as defi-
nite evidence of TBM.
The patients underwent detailed clinical examination. Con-
sciousness was assessed using the Glasgow coma scale (GCS), and
cognitive function by the mini mental state examination (MMSE)
in the patients who could cooperate. Cognitive impairment was
diagnosed when the score was below 22 in patients with 0–4 years
of schooling, 26 in those with 5–8 years and below 29 for those with
9 years or more [6]. Cranial nerve palsies, focal weakness, muscle
tone, reflexes and sensation were noted. The CSF was examined for
cells, protein, sugar, AFB, fungi and bacteria. CT before and after
contrast medium was carried out in all patients and the presence of
hydrocephalus, infarcts, exudates and tuberculomas was noted. We
graded the severity of meningitis as: stage I: meningitis only;
stage II: meningitis with neurological signs; and stage III: menin-
gitis with altered sensorium [7].
All patients received four-drug antituberculous therapy
(RHZE); in children we prescribed streptomycin instead of eth-
ambutol. A ventriculoperitoneal (VP) shunt was carried out as and
when indicated. Anticonvulsants were prescribed for seizures.
Most patients were admitted for 4–10 weeks and during their
hospital stay CT was repeated if they deteriorated clinically. They
were followed up clinically and radiologically at 3 and 6 months.
Cognitive impairment, visual loss, optic atrophy, motor deficits,
recurrence of seizures and other neurological deficits were noted.
CT studies were compared with the previous examinations and we
noted new lesions, plus persistence or disappearance of previous
abnormalities. Functional outcome at 3 and 6 months was assessed
using the Barthel index (BI) score as poor (<12), partial (12–19)
and complete (20) recovery [5].
We correlated various clinical and radiological parameters with
neurological sequelae using the chi-square test. To assess factors
associated with initial deterioration on treatment, we looked at
clinical (age, sex, duration of illness, weakness, seizures, GCS, BCG
vaccination, cranial nerve palsies, stage of meningitis, BI score,
drug-induced hepatitis, use of corticosteroids), laboratory (sedi-
mentation rate, CSF cells and protein) and CT (exudates, hydro-
cephalus, infarcts and tuberculomas) findings employing univariate
logistic regression analysis.
Results
The patients’ age ranged between 6 and 80 years, mean
35.2 years; 13 were female and four children. The du-
ration of illness was 0.5–12 months, mean 2.8 months.
On admission, most patients had severe meningitis: 20
were in stage III and six in stage II. Two patients were
deeply comatose (GCS<6) and 11 had moderately
impaired consciousness (GCS 6–12). There were 13 who
had seizures, partial in three and generalised tonic/clonic
in ten. Cranial nerve palsies were present in 15 patients,
six had papilloedema and nine focal motor deficits
(Table 1). Cranial CT was abnormal on admission in
28 patients, including hydrocephalus in 15 (communi-
cating in 12), exudates in 15 (mild in ten, moderate in
five), infarcts in ten (cortical in three, subcortical in five
and in the brain stem in two) and tuberculomas in 13
(supratentorial in eight, infratentorial in four and both
in one).
On antituberculous treatment, ten patients deterio-
rated during first 6 weeks of their admission, the mean
GCS score falling to11.4 from 12.5. There was two-stage
deterioration in severity of meningitis in one patient, a
one-stage deterioration in another, new motor deficits
appeared in four patients and four more developed optic
atrophy. CT in these patients revealed either new hy-
drocephalus, infarcts, exudates or tuberculomas, or
progression of existing abnormalities (Table 2). We in-
serted a VP shunt in four patients, following which hy-
drocephalus became less marked in three; in one patient
the shunt had to be revised.
At 3-month follow-up all but four patients were
conscious; 17 had improved from stage III to stage II
and one from stage III to stage I. A patient with para-
paresis improved but one more patient developed a
quadriparesis; three more patients developed optic at-
rophy. The MMSE could be performed in 22 patients
(mean score 23) and 11 had cognitive impairment. There
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were 12 patients who had a poor, four partial and 14
complete recovery; one patient had died. CT was ab-
normal in 29 patients: three had developed hydroceph-
alus, four patients had developed infarcts, exudates had
resolved in five patients and tuberculomas were un-
changed. One patient each had diffuse cortical atrophy
and a subdural hygroma. One patient underwent a VP
shunt and another a revision of a shunt.
At 6 months 17 patients had complete, four partial and
nine poor recovery .These last nine patients did not show
any improvement from their 3month status. Neurological
sequelae were present in all but five patients (Table 1). CT
became normal in four patients but remained abnormal in
26.Hydrocephalus had resolved in four patients, who had
all undergone VP shunting, exudates and tuberculomas
had disappeared in six patients each but infarcts remained
the same. In one patient a tuberculoma resolved by cal-
cification (Table 2; Figs. 1, 2, 3).
Correlating the worst CT appearances with 6-month
clinical sequelae, a motor deficit correlated with exudates
(X2=3.96, df=1, P<0.05) and infarcts (X2=12.38
df=1, P<0.05). Hydrocephalous and tuberculoma did
not correlate with sequelae. Correlating the 6-month
CT findings with neurological sequelae at 6 months,
motor deficit correlated with infarcts (X2=12.381, df=1,
P<0.05), cognitive impairment with exudates {X2=
4.531, df=1, P<0.05) and tuberculomas {X2=3.545,
df=1, P<0.05) (Table 3). Functional outcome at
6 months was related to the presence of exudates at
6 months (X2= 6.86, df=2, P<0.05) and infarcts (X2=
8.06, df=2, P<0.05).
As regards factors responsible for worsening during
initial treatment, logistic regression analysis indicated
that the presence of motor deficits on admission
(Z=2.10) and the GCS (Z=1.97) were significantly re-
lated to deterioration. Male sex (Z=1.15), stage of TBM
(Z=1.49), CSF protein level (Z=1.62) and initial ADL
score (Z=1.62) had borderline significance.
Discussion
In our study one-third patients with TBM deteriorated
in the first 6 weeks of treatment. A number of clinical
and radiological phenomena in TBM may be due to
ongoing infection or inflammation which could result in
continued deterioration. This may be attributed to re-
duced drug concentrations due to the blood-brain bar-
rier, the use of corticosteroids and altered immunity.
None of our patients was on corticosteroids and there
was no apparent immunosuppression or compromise.
The initial deteriorations on treatment were significantly
related to weakness and the GCS. Weakness in TBM
may suggest underlying infarcts due to ongoing tuber-
Table 2 Serial CT findings
Initial
(31)
Admission–
6 weeks (10)
3 months
(31)
6 months
(30)
Increased New
Hydrocephalus 15 6 2 20 16
Exudates 15 3 4 14 8
Infarction 10 2 4 16 16
Tuberculoma 13 1 2 15 9
Calcification 1
Ventriculoperitoneal
shunt
4 2
Table 1 Serial clinical findings. MMSE Mini mental state examination
Initial
(31 patients)
Admission–6 weeks
(31 patients, 10 worsened)
3 months
(31 patients)
6 months
(30 patients)
Mean Glasgow coma score 12.5 11.4 14.7 15
Stage I 5 4 5 5
Stage II 6 5 22 25
Stage III 20 22 4 0
Focal deficit 9 13 13 11
Hemiparesis 6 9 9 7
Paraparesis 1 1 0 0
Quadriparesis 2 3 4 4
Optic atrophy 2 6 9 9
Ophthalmoplegia 10 11 11 7
Cognitive impairment 11/22 (mean MMSE
score )23)
13/24 (mean
MMSE score –24)
Ataxia 2 2 3 2
Deafness 2 2 2 2
Activities of daily living score
Poor recovery 12
Partial recovery 4 9
Complete recovery 14 4
Dead 1 17
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culous vasculopathy [8]. The latter may progress and
result in new infarcts, producing both clinical and ra-
diological deterioration, including an altered sensorium.
Low GCS score and borderline significance of stage of
TBM and low ADL score also suggest that more
severe forms of meningitis are more likely to show dete-
rioration.
BCG vaccination, therapy-induced hepatitis and
corticosteroids, however, were not significantly related
to deterioration. BCG vaccination has been reported to
be effective in limiting the severity of tuberculosis and
CNS invasion, especially in children [9]. In another
study, however, BCG vaccine had little effect on the
clinical findings or subsequent CNS tuberculosis [10].
Hepatitis induced by therapy, resulting in withdrawal of
rifampacin and isoniazid for 2–3 weeks has been asso-
ciated with poor outcome [11]. Lack of correlation with
drug-induced hepatitis in our patients may be due to
poor CSF penetration of rifampacin. Outcome has not
changed in miliary tuberculosis before and after the in-
troduction of rifampacin [12, 13]. Corticosteroids have
been reported to reduce the sequelae of TBM [14] but in
our earlier study, corticosteroid therapy was not related
to 6-month outcome [5]; similar observations have been
reported from Thailand [15].
The initial deterioration in TBM could be due to an
immunoallergic reaction resulting in liberation of cyto-
kines and lymphokines and subsequent appearance or
organisation of basal exudates, termed a ‘‘paradoxical
response’’. This is an uncommon hypersensitivity reac-
tion to massive release of tuberculoprotein into the
subarachnoid space, manifest clinically within days of
commencement of treatment; the patient may rapidly
deteriorate to coma or even death [16]. This therapeutic
paradox has been regarded as pathognomonic of TBM
[17]. The initial deterioration in at least two of our
patients could be due to a paradoxical response. One, in
stage I on admission, deteriorated to stage III and also
developed a hemiplegia after a few days of treatment.
CT, normal on admission, revealed hydrocephalus with
enhancing exudates and corona radiata infarction. He
underwent a VP shunt and started improving after
1 month . Another patient, in stage II with mild right-
sided weakness on admission, had increased headache
and vomiting after initiation of therapy and deteriorated
to stage III with increased weakness. Repeat CT showed
an increase in hydrocephalus with enhancing exudates
and a fresh basal ganglia infarct. He also improved
4–6 weeks after a VP shunt.
By 3 months, however, most of our patients, including
those who deteriorated initially either became stable or
started improving. Radiological follow up revealed new
hydrocephalus and infarcts, both of which could be due to
organisation of basal exudates, in three patients each.
Fig. 2A, B A patient with stage I TBM had a normal CT at
presentation. A After 1 week of antituberculous therapy he
deteriorated to stage III and CT showed hydrocephalous, periven-
tricular capping and infarcts in the basal ganglia. B At 6 months,
following a ventriculoperitoneal shunt, CT revealed regression of
hydrocephalus and persist basal ganglia infarcts
Fig. 1A–C Contrast-enhanced CT of a patient with stage II
tuberculous meningitis (TBM). A There is a right enhancing disc
lesion with perifocal oedema which disappeared after 3 months of
antituberculous therapy B. C At 6 months the patient developed
another disc lesion with perifocal oedema in the inferior frontal
region. CT also showed dilatation of the posterior horn of the
lateral ventricle and the 3rd ventricle. There were mild exudates in
the sylvian fissure, but the patient was improving clinically
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At 6 months no patient worsened clinically or ra-
diologically but 26 of 30 CT studies remained abnor-
mal. In one serial study of CT and MRI in TBM all
abnormal CT findings except infarcts disappeared [18].
This difference from our study could be attributed to
milder illness and use of MRI in the previous study.
More severe illness in our patients is evidenced by
stage III meningitis in 65% and hydrocephalus in 50%.
In a clinical and CT follow-up of 25 patients with
TBM, 18 had hydrocephalus on admission and hydro-
cephalus developed in three during follow-up. In seven
patients exudates persisted for 11–96 months. New tu-
berculomas appeared even after 7 months of treatment
[3]. This study, however, did not have a uniform follow-
up protocol and nor did it systematically address initial
clinicoradiological deterioration and factors associated
with it. In another study [19], there was initial deterio-
ration in a subgroup of patients during treatment but the
factors associated with this were not examined.
It can be concluded that close monitoring of patients
with TBM during the first 6 weeks of treatment is es-
sential as one third may deteriorate, especially those
with low GCS and weakness. Repeating CT can be
valuable in their management. Most CT abnormalities
persist even after 6 months despite clinical improvement.
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Fig. 3A–F A patient with
stage III TBM. A, B CT reveals
communicating hydrocephalus.
C, D After about 6 weeks’
hospital stay the patient deteri-
orated, with decreased visual
acuity and quadriparesis. CT
showed increased hydrocepha-
lus, enhancing exudates and
multiple infarcts. E, F CT at 3
months showed only minimal
improvement in hydrocephalus
and exudates although the pa-
tient had improved clinically
Table 3 Clinical sequelae and CT correlations
Cognitive im-
pairment
Weakness Optic atrophy
Yes No Yes No Yes No
Worst CT (within 3 months)
Hydrocephalus
Yes 6 6 8 12 5 15
No 7 5 3 7 4 6
Exudate
Yes 10 6 10 9 7 12
No 3 5 1 10 2 9
Infarct
Yes 8 4 11 5 5 11
No 5 7 0 14 4 10
Tuberculoma
Yes 9 4 8 7 5 10
No 4 7 3 12 4 11
6 months
Hydrocephalus
Yes 7 4 7 9 3 13
No 6 7 4 10 6 8
Exudate
Yes 6 0 6 2 4 4
No 7 11 5 17 5 17
Infarct
Yes 7 4 11 5 5 11
No 6 7 0 14 4 10
Tuberculoma
Yes 7 1 4 5 4 5
No 6 10 7 14 5 16
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